Ophthalmology Department, Rothschild Foundation Hospital, Paris, France.
Ophthalmology Department, Cochin Hospital, Paris, France.
Ocul Immunol Inflamm. 2021 Jan 2;29(1):9-13. doi: 10.1080/09273948.2020.1763405. Epub 2020 Jul 9.
Describe our experience with tocilizumab in the treatment of refractory relapsing polychondritis with ocular involvement. Retrospective consecutive interventional case series that included all patients that received tocilizumab for the treatment of relapsing polychondritis with ocular manifestations. Three cases were selected and the duration of tocilizumab treatment ranged from 1 to 2 years. One of our patients received tocilizumab as a first-line immunosuppressive treatment directly after prednisone. All achieved complete response to tocilizumab 1 month after treatment initiation. No advert events were reported during the follow-up period except for transient neutropenia without any associated infection. Our three cases suggest that tocilizumab may be an effective and safe treatment for ocular manifestation associated with relapsing polychondritis.
描述我们使用托珠单抗治疗伴有眼部受累的难治性复发性多软骨炎的经验。这是一项回顾性连续干预性病例系列研究，纳入了所有接受托珠单抗治疗伴有眼部表现的复发性多软骨炎的患者。选择了 3 例患者，托珠单抗治疗的持续时间为 1 至 2 年。我们的 1 例患者在泼尼松后直接将托珠单抗作为一线免疫抑制治疗。所有患者在治疗开始后 1 个月均对托珠单抗完全应答。在随访期间，除了短暂的中性粒细胞减少而无任何相关感染外，没有报道其他不良事件。我们的 3 例病例提示，托珠单抗可能是治疗伴有复发性多软骨炎的眼部表现的一种有效且安全的治疗方法。
